Assignee: TEVA Pharmaceutical Industries, Ltd.

Location: Petach-Tikva, IL
No. of patents: 27

Number	Title	Issue Date
8163960	Process for preparing and drying solid rasagiline base Disclosed is crystalline R(+)-N-propargyl-1-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the...	04/24/2012
8067473	Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amoun...	11/29/2011
7989473	Stable laquinimod preparations The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier. ...	08/02/2011
7968749	Process for preparing and drying solid rasagiline base Disclosed is crystalline R(+)-N-propargyl-l-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the...	06/28/2011
7968511	Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are ...	06/28/2011
7923215	Process for the measurement of the potency of glatiramer acetate The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. ...	04/12/2011
D634422	Auto injection device	03/15/2011
D634421	Auto injection device with over mould grip	03/15/2011
7884208	Crystals of laquinimod sodium, and process for the manufacture thereof Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics. ...	02/08/2011
7855233	Citrate salt of Rasagiline The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof. ...	12/21/2010
7855176	Reduced volume formulation of glatiramer acetate and methods of administration A method for reducing frequency of relapses in a human patient afflicted with relapsing-remitting multiple sclerosis (RRMS) comprising administering to the patient 0.5 ml of an aqueous pharmaceutical solution of 20 mg glatiramer acetate and 20 mg mannitol. ...	12/21/2010
7750051	Crystalline solid rasagiline base The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof. ...	07/06/2010
7749541	Rasagiline formulations of improved content uniformity Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses. ...	07/06/2010
7632841	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate. ...	12/15/2009
7619117	Rasagiline formulations and processes for their preparation The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure:	11/17/2009
7598420	Rasagiline formulations and processes for their preparation The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure:	10/06/2009
7572834	Rasagiline formulations and processes for their preparation The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure:	08/11/2009
7547806	Tannate salt of rasagiline The subject invention provides rasagiline tannate, compositions and a process for manufacture thereof. ...	06/16/2009
7495072	Process for preparation of mixtures of polypeptides using purified hydrobromic acid The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides ...	02/24/2009
7491847	Methods for isolating propargylated aminoindans A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a sal...	02/17/2009
7435741	2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate. ...	10/14/2008
7429374	Process for the measurement of the potency of glatiramer acetate The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. ...	09/30/2008
7396860	Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis The subject invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject in need of such treatment comprising administering to the subject R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof alone or in combinatio...	07/08/2008
7375249	Process for the synthesis of enantiomeric indanylamine derivatives A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the...	05/20/2008
7335685	Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof Disclosed is crystalline ladostigil tartrate of a specified density, compositions, including pharmaceutical compositions comprising such ladostigil tartrate, and a process for the manufacture thereof. ...	02/26/2008
7294687	Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-...	11/13/2007
RE39616	Aminoindan derivatives This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is...	05/08/2007

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: TEVA Pharmaceutical Industries, Ltd.